[HTML][HTML] Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder

JY Liu, YH Li, HX Lin, YJ Liao, SJ Mai, ZW Liu… - BMC cancer, 2013 - Springer
JY Liu, YH Li, HX Lin, YJ Liao, SJ Mai, ZW Liu, ZL Zhang, LJ Jiang, JX Zhang, HF Kung…
BMC cancer, 2013Springer
Background Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is
a key regulator of organ size and a candidate human oncogene in multiple tumors.
However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB)
and its clinical/prognostic significance are unclear. Methods In this study, the methods of
quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and
immunohistochemistry (IHC) were utilized to investigate mRNA/protein expression of YAP 1 …
Background
Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
Methods
In this study, the methods of quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and immunohistochemistry (IHC) were utilized to investigate mRNA/ protein expression of YAP 1 in UCBs. Spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the data.
Results
Up-regulated expression of YAP 1 mRNA and protein was observed in the majority of UCBs by qRT-PCR and Western blotting, when compared with their paired normal bladder tissues. By IHC, positive expression of YAP 1 was examined in 113/213 (53.1%) of UCBs and in 6/86 (7.0%) of normal bladder specimens tissues. Positive expression of YAP 1 was correlated with poorer differentiation, higher T classification and higher N classification (P < 0.05). In univariate survival analysis, a significant association between positive expression of YAP 1 and shortened patients’ survival was found (P < 0.001). In different subsets of UCB patients, YAP 1 expression was also a prognostic indicator in patients with grade 2 (P = 0.005) or grade 3 (P = 0.046) UCB, and in patients in pT1 (P = 0.013), pT2-4 (P = 0.002), pN- (P < 0.001) or pT2-4/pN- (P = 0.004) stage. Importantly, YAP 1 expression (P = 0.003) together with pT and pN status (P< 0.05) provided significant independent prognostic parameters in multivariate analysis.
Conclusions
Our findings provide evidences that positive expression of YAP 1 in UCB may be important in the acquisition of an aggressive phenotype, and it is an independent biomarker for poor prognosis of patients with UCB.
Springer